Why the study?
New-onset atrial fibrillation is a common complication during AMI and can be asymptomatic, but the clinical implications of asymptomatic episodes require further characterization.
Does the presence of symptoms in new-onset atrial fibrillation affect short- and long-term mortality in patients with acute myocardial infarction?
Does the presence of symptoms in new-onset atrial fibrillation affect short- and long-term mortality in patients with acute myocardial infarction?
In patients with acute myocardial infarction, symptomatic new-onset atrial fibrillation predicts in-hospital mortality, while asymptomatic new-onset atrial fibrillation is associated with worse long-term survival.
Answers are grounded in this paper and cite their sources.
Symptomatic post-MI NOAF flags in-hospital risk while asymptomatic links to long-term mortality; leaves open whether symptom-guided monitoring alters outcomes.
Background: New-onset atrial fibrillation (NOAF) is a common complication during acute myocardial infarction (AMI) and sometimes can be completely asymptomatic, but the clinical implications of these asymptomatic episodes require further characterization. The objective of this study was to investigate the short- and long-term prognostic impact of post-MI NOAF based on the presence of AF-related symptoms. Methods: The New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in ShangHai (NOAFCAMI-SH) registry was a retrospective cohort including participants with AMI without a documented history of AF. Patients with NOAF were divided into two groups according to the AF-related symptoms. The primary endpoint was all-cause mortality. Results: Of 2,399 patients included, 278 (11.6%) developed NOAF of whom 145 (6.0%) with asymptomatic episodes and 133 (5.5%) with symptomatic ones. During hospitalization, 148 patients died [106, 10, and 32 in the sinus rhythm (SR), asymptomatic, and symptomatic NOAF groups, respectively]. After multivariable adjustment, only symptomatic NOAF was associated with in-hospital mortality [odds ratio (OR): 2.32, 95% confidence interval (CI): 1.36–3.94] compared with SR. Over a median follow-up of 2.7 years, all-cause mortality was 3.2, 12.4, and 11.8% per year in the SR, asymptomatic, and symptomatic NOAF groups, respectively. After adjustment for confounders, it was the asymptomatic NOAF [hazard ratio (HR): 1.61, 95% CI: 1.09–2.37) rather than the symptomatic one (HR: 1.37, 95% CI: 0.88–2.12) that was significantly related to mortality. Similar results were also observed for cardiovascular mortality [HRs and 95% CI were 1.71 (1.10–2.67) and 1.25 (0.74–2.11) for asymptomatic and symptomatic NOAF, respectively]. Both asymptomatic and symptomatic NOAF episodes were associated with heart failure, whereas only those with symptomatic NOAF were at heightened risk of ischemic stroke. Our exploratory analysis further identified patients with asymptomatic high-burden NOAF as the highest-risk population (mortality: 19.6% per year). Conclusion: Among patients with AMI, symptomatic NOAF is related to in-hospital mortality and asymptomatic NOAF is associated with poor long-term survival. Registration: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT03533543.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: